Sinopharm (01099) rose more than 5% in the afternoon, up 4.77% to HKD 21.95 at the time of publication, with a turnover of HKD 72.67 million.
According to the Zhongtong Finance app, Sinopharm (01099) rose more than 5% in the afternoon, up 4.77% to HKD 21.95 at the time of publication, with a turnover of HKD 72.67 million.
On the news side, on the evening of June 16, the China National Pharmaceutical Group announced that Bai Zhongquan took over as party secretary and chairman of China Meheco Group. The layout of the China National Pharmaceutical Group's listed companies can be divided into: Sinopharm, China National Accord Medicines Corporation, China National Medicines Corporation, the three major pharmaceutical circulation listed companies, Traditional Chinese Medicine and Taiji Industry two major Chinese medicine listed companies, Tian Tan Biological and Shen Zhen Weiguang Biological two major blood product companies, as well as the leading listed companies in the chemical pharmaceutical industry Modern Pharma and the leading in vitro diagnostics listed company Beijing Strong Biotechnologies, Inc.
Huafu Securities previously stated that the national reform will continue to deepen, and the potential of the national drugs system's targets is huge. Under the environment of deepening national reform and the new "National Nine Articles", the head central enterprises are expected to realize the catalysis of advantages resource integration, operational improvement, personnel optimization, and dividend enhancement etc. Sinopharm is a central enterprise group with a huge system, abundant resources and great potential for improvement. The group has made major personnel adjustments and merger and acquisition integration, and continues to realize the effects of reform.